Matthew Frankel M.D.

Matthew Frankel MD currently serves as the Chief Medical Officer at Nocion Therapeutics, Inc., focusing on the development of Taplucainium for chronic cough. With a rich background in medical affairs and clinical development, previous roles include Chief Medical Officer at Chemomab Therapeutics, overseeing drug development for fibrotic and inflammatory diseases, and Vice President at Boehringer Ingelheim, leading late phase clinical and medical affairs in oncology, immunology, pulmonary, and CNS. Matthew has also held leadership positions at Novartis, Sandoz, Reata Pharmaceuticals, FibroGen, Facet Biotech, and Schering Plough, contributing significantly to various clinical trials and drug development initiatives across multiple therapeutic areas. Educational qualifications include an MD from the University of California, Los Angeles School of Medicine, and an MBA from Northwestern University - Kellogg School of Management.